The company plans to develop its subsidiary GenoBio’s GenoCTC v5 as a versatile device for cancer across all stages

South Korean biotech company Gencurix Inc. announced on Wednesday its subsidiary GenoBio has received approval from the US Food and Drug Administration (FDA) for the “GenoCTC v5,” a circulating tumor cells (CTCs)-based breast cancer prognosis analysis device.

According to Gencurix, CTCs are tumor cells found in the blood, which are used for monitoring cancer treatment effectiveness and as markers for cancer metastasis.

GenoBio had previously presented research results at the San Antonio Breast Cancer Symposium in December last year, predicting the prognosis of breast cancer patients using this device.